- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
- Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
- Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6526 |
---|---|
High | 0.655 |
Low | 0.602 |
Bid | 0.6273 |
Offer | 0.64 |
Previous close | 0.6361 |
Average volume | 4.37m |
---|---|
Shares outstanding | 151.01m |
Free float | 142.38m |
P/E (TTM) | -- |
Market cap | 96.06m USD |
EPS (TTM) | -0.897 USD |
Data delayed at least 15 minutes, as of Apr 17 2024 21:00 BST.
More ▼